Erica Andersen-Nissen

Cape Town HVTN Immunology Laboratory

Laboratory Director

Dr. Andersen-Nissen directs cellular immunology studies of specimens from HIV Vaccine Trials Network (HVTN) studies in Southern Africa. She holds a Senior Staff Scientist position at the Fred Hutchinson Cancer Research Center and is an Honourary Research Associate at the University of Cape Town in the Division of Medical Virology. Dr. Andersen-Nissen completed her PhD in immunology at the University of Washington in Seattle in June 2006 under the mentorship of Dr. Alan Aderem. She then pursued a postdoctoral fellowship in Dr. Julie McElrath’s laboratory at the Fred Hutchinson Cancer Research Center where she profiled innate immune responses induced by candidate HIV vaccines, providing new information about human immune responses to experimental adjuvants and viral vaccine vectors. Erica relocated to Cape Town in January 2013 to start CHIL and is studying innate and adaptive immune responses elicited by HIV and TB vaccines in Southern African populations to identify immune correlates of risk and protection.

Erica Andersen-Nissen

Cape Town HVTN Immunology Laboratory

Laboratory Director

Dr. Andersen-Nissen directs cellular immunology studies of specimens from HIV Vaccine Trials Network (HVTN) studies in Southern Africa. She holds a Senior Staff Scientist position at the Fred Hutchinson Cancer Research Center and is an Honourary Research Associate at the University of Cape Town in the Division of Medical Virology. Dr. Andersen-Nissen completed her PhD in immunology at the University of Washington in Seattle in June 2006 under the mentorship of Dr. Alan Aderem. She then pursued a postdoctoral fellowship in Dr. Julie McElrath’s laboratory at the Fred Hutchinson Cancer Research Center where she profiled innate immune responses induced by candidate HIV vaccines, providing new information about human immune responses to experimental adjuvants and viral vaccine vectors. Erica relocated to Cape Town in January 2013 to start CHIL and is studying innate and adaptive immune responses elicited by HIV and TB vaccines in Southern African populations to identify immune correlates of risk and protection.